• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Salarius Pharmaceuticals Inc.

    4/29/22 4:31:52 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLRX alert in real time by email
    SC 13G 1 sched13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No.   )*
     

     
    Salarius Pharmaceuticals, Inc.
     
     
    (Name of Issuer)
     

     
    Common Stock, par value $0.0001 per share
     
     
    (Title of Class of Securities)
     

     
    79400X107
     
     
    (CUSIP Number)
     

     
    April 26, 2022
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Fund II LP
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    2,969,718
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    2,969,718
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,969,718(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    5.3%(2)
     
    12
    Type of Reporting Person (See Instructions)
    PN
     
    (1) The reporting person’s ownership consists of (a) 2,969,718 common shares and (b) warrants to purchase 2,227,289 common shares (the “Warrants”), however, since the Warrants are not exercisable within 60 days of the date hereof, the reporting person’s beneficial ownership of the Warrants has been excluded.
    (2) Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Partners II LLC
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    2,969,718
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    2,969,718
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,969,718 (1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    5.3%(2)
     
    12
    Type of Reporting Person (See Instructions)
    OO
     
    (1) The reporting person’s ownership consists of (a) 2,969,718 common shares and (b) 2,227,289 Warrants, however, since the Warrants are not exercisable within 60 days of the date hereof, the reporting person’s beneficial ownership of the Warrants has been excluded.
    (2) Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.



    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Jeff Easton
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    2,969,718
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    2,969,718
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,969,718(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    5.3%(2)
     
    12
    Type of Reporting Person (See Instructions)
     
    IN
     
    (1) The reporting person’s ownership consists of (a) 2,969,718 common shares and (b) 2,227,289 Warrants, however, since the Warrants are not exercisable within 60 days of the date hereof, the reporting person’s beneficial ownership of the Warrants has been excluded.
    (2) Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.



    Item 1.
    (a)
    Name of Issuer
     
     
    Salarius Pharmaceuticals, Inc.
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    2450 Holcombe Blvd., Suite X
    Houston, TX 77021

    Item 2.
    (a)
    Name of Person Filing
     
     
    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):
     
    •  Lind Global Fund II LP, a Delaware limited partnership;
    •  Lind Global Partners II LLC, a Delaware limited liability company; and
    •  Jeff Easton, an individual and a citizen of the United States of America.
     
    Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    The address of the principal business office for each of the Reporting Persons is:
     
    444 Madison Ave, Floor 41
    New York, NY 10022
     
    (c)
    Citizenship
     
     
    See Row 4 of cover page for each Reporting Person.
     
    (d)
    Title of Class of Securities
     
    Common Stock, par value $0.0001 per share
    (e)
    CUSIP Number
     
     
    79400X107
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    Not applicable.
    Item 4.
    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a)
    Amount Beneficially Owned
     
     
     See Row 9 of cover page for each Reporting Person.
     
    (b)
    Percent of Class
     
     
    See Row 11 of cover page for each Reporting Person.

    (c)
    Number of shares as to which such person has:
     
     
    (i)
    sole power to vote or to direct the vote
       

    See Row 5 of cover page for each Reporting Person.
     
     
    (ii)
    shared power to vote or to direct the vote
       
     
    See Row 6 of cover page for each Reporting Person.
     
     
    (iii)
    sole power to dispose or to direct the disposition of
       

    See Row 7 of cover page for each Reporting Person.
     
     
    (iv)
    shared power to dispose or to direct the disposition of
       
     
    See Row 8 of cover page for each Reporting Person.
     

    Item 5.
    Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.
    Notice of Dissolution of Group
    Not applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits     Exhibit

    99.1                  Joint Filing Agreement by and among the Reporting Persons.


    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    April 29, 2022

    LIND GLOBAL FUND II LP
       
    By:
     
    Lind Global Partners II LLC
     
     
    its General Partner
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    LIND GLOBAL PARTNERS II LLC
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    JEFF EASTON

    /s/ Jeff Easton



    Get the next $SLRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLRX

    DatePrice TargetRatingAnalyst
    3/11/2022$5.00 → $4.00Buy
    HC Wainwright & Co.
    8/25/2021$5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SLRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

      CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts Institute of Technology (MIT) Professor and Moderna co-founder Robert S. Langer, ScD will join the company's Scientific Advisory Board (SAB) upon the successful completion of Decoy's merger with Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX). As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals signed a definitive agreement under which Decoy Therapeutics will merge with a wholly owned subsidiary of Salarius Pharmaceuticals, with t

      4/16/25 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses

      CAMBRIDGE, Mass. and HOUSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide-conjugate therapeutics, announced that a series of antiviral drug candidates previously designed by its IMP3ACT™ platform to be broadly effective against viruses of the paramyxoviridae family also showed promising in silico activity against measles and Nipah viruses. As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) signed a definitive merger agreement pursuant to which Decoy will merge with a wholly owned subsidiary of Salarius, subject to satisfaction of th

      3/26/25 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

      Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating respiratory viruses and cancer Updates expected later this year from the MD Anderson Cancer Center (MDACC) investigator-initiated Phase 1/2 clinical trial of seclidemstat in combination with azacitidine to treat hematologic cancers HOUSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today repor

      3/24/25 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Salarius Pharmaceuticals Inc.

      SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

      11/14/24 4:38:31 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Salarius Pharmaceuticals Inc.

      SC 13G - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

      2/14/24 3:54:30 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Salarius Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

      2/13/23 4:30:18 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Salarius Pharmaceuticals Inc.

      PRE 14A - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)

      5/15/25 5:18:30 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Salarius Pharmaceuticals Inc.

      DEF 14A - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)

      5/15/25 5:03:13 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Salarius Pharmaceuticals Inc.

      10-Q - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)

      5/14/25 5:02:39 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    Financials

    Live finance-specific insights

    See more
    • Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH

      HOUSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, will hold a conference call with slides to discuss recent clinical and preclinical data from its lead programs on December 14, 2022 at 11:00 a.m. Eastern time. Management will review recently announced interim results from its ongoing Phase 1/2 trial with seclidemstat in Ewing sarcoma and FET-rearranged sarcomas, as well as new clinical data from MD Anderson Cancer Center's study with seclidemstat plus azacytidine in hematological cancer

      12/8/22 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

      60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing Sarcoma First-Relapse Patients No Disease Progression Observed in Either First- or Second-Relapse Ewing Sarcoma Patients Who Achieved Confirmed Disease Control HOUSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer in need of new treatment options, announces interim clinical trial results from the company's Phase 1/2 trial of its novel oral, reversible, targeted LSD1 inhibitor, seclidemstat, as a treatment fo

      12/1/22 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

      HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today reported financial results for the three and six months ended June 30, 2022, and provided a business update. Highlights of the quarter and recent weeks included: Financial Highlights Cash and equivalents were $22.6 million as of June 30, 2022, compared with $29.2 million as of December 31, 2021Tightly managed expenses while progressing toward multiple near-term milestonesNet loss of $4.7 million, or $0.09 per share, compared with net loss of $3.1 million, or $0.07 per share,

      8/8/22 8:30:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Arthur David J.

      4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

      4/12/24 4:50:27 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Rosenblum Mark J

      4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

      2/22/24 4:37:10 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Mcvicar William K.

      4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

      2/22/24 4:29:33 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Salarius Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Salarius Pharmaceuticals with a rating of Buy and set a new price target of $4.00 from $5.00 previously

      3/11/22 6:32:47 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Salarius Pharmaceuticals with a new price target

      HC Wainwright & Co. initiated coverage of Salarius Pharmaceuticals with a rating of Buy and set a new price target of $5.00

      8/25/21 6:10:11 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

      CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts Institute of Technology (MIT) Professor and Moderna co-founder Robert S. Langer, ScD will join the company's Scientific Advisory Board (SAB) upon the successful completion of Decoy's merger with Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX). As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals signed a definitive agreement under which Decoy Therapeutics will merge with a wholly owned subsidiary of Salarius Pharmaceuticals, with t

      4/16/25 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

      HOUSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that Daniela Santiesteban, Ph.D., has been named Director of the Company's new targeted protein degradation program. In this newly created position, Dr. Santiesteban will assume responsibility for overseeing the development of SP-3164, the program's lead drug candidate, and advancing it into clinical trials. Her appointment immediately follows Salarius' recent strategic expansion into the targeted protein degradation field through its acquisitio

      2/3/22 7:30:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care